MannKind Corporation (Nasdaq: MNKD) announced that it has met the primary endpoints of its final two pivotal Phase 3 studies of AFRESATM, the company's ultra rapid acting, inhaled insulin product. The company expects to disclose more details of the top-line data from these studies in patients with type 1 and type 2 diabetes (studies 030 and 102) by mid-December.
[Sadece Üyeler Görebilir. Üye olmak için tiklayiniz...]
MannKind Reports Positive Results From Final Two Pivotal Phase 3 Clinical Studies In Type 1 And Type
Normal Mod
